Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nugent

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
NPJ Vaccines|August 23, 2018
Production, quality control, stability, and potency of cGMP-produced <i>Plasmodium falciparum</i> RH5.1 protein vaccine expressed in <i>Drosophila</i> S2 cellsJing Jin, Richard D Tarrant, Emma J Bolam, et al.
Med (New York, N.Y.)|August 12, 2023
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adultsSarah E Silk, Wilmina F Kalinga, Ivanny M Mtaka, et al.
Medrxiv : the Preprint Server for Health Sciences|June 6, 2022
Impact of a blood-stage vaccine on <i>Plasmodium vivax</i> malariaMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
Science Translational Medicine|July 12, 2023
Vaccination with <i>Plasmodium vivax</i> Duffy-binding protein inhibits parasite growth during controlled human malaria infectionMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
JAMA|February 23, 2021
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical TrialJonathan E Sevransky, Richard E Rothman, David N Hager, et al.
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
Nature Communications|September 25, 2025
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infectionMimi M Hou, Adam C Harding, Natalie M Barber, et al.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
NPJ Vaccines|August 23, 2018
Production, quality control, stability, and potency of cGMP-produced <i>Plasmodium falciparum</i> RH5.1 protein vaccine expressed in <i>Drosophila</i> S2 cellsJing Jin, Richard D Tarrant, Emma J Bolam, et al.
Med (New York, N.Y.)|August 12, 2023
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adultsSarah E Silk, Wilmina F Kalinga, Ivanny M Mtaka, et al.
Medrxiv : the Preprint Server for Health Sciences|June 6, 2022
Impact of a blood-stage vaccine on <i>Plasmodium vivax</i> malariaMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
Science Translational Medicine|July 12, 2023
Vaccination with <i>Plasmodium vivax</i> Duffy-binding protein inhibits parasite growth during controlled human malaria infectionMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
JAMA|February 23, 2021
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical TrialJonathan E Sevransky, Richard E Rothman, David N Hager, et al.
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
Nature Communications|September 25, 2025
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infectionMimi M Hou, Adam C Harding, Natalie M Barber, et al.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Pageof 13